Targets › CD24
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Aug 2027.
May have a pivotal role in cell differentiation of different cell types. Signaling could be triggered by the binding of a lectin-like ligand to the CD24 carbohydrates, and transduced by the release of second messengers derived from the GPI-anchor. (UniProt, P25063)
Open in Phaseline: the race on CD24, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| OncoC4 | ONC-783 Bispecific antibody targeting CD24 and CD3 | CD24, CD3 | Phase 1 | Advanced Solid Tumor | Aug 2027 |
| Pheast Therapeutics | PHST001 anti-CD24 macrophage checkpoint inhibitor | CD24 | Phase 1 | Advanced Solid Tumors | Apr 2029 |
Advanced Solid Tumor (1) Advanced Solid Tumors (1)
antibody (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.